Back to top
more

Acorda Therapeutics, Inc. (ACOR)

(Delayed Data from NSDQ)

$11.74 USD

11.74
1,452,260

+1.16 (10.96%)

Updated May 3, 2019 04:00 PM ET

After-Market: $11.74 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Fall Y/Y

by Zacks Equity Research

CRISPR Therapeutics (CRSP) misses estimates for both earnings and revenues in the fourth quarter of 2020. Focus on pipeline development.

Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) beats both earnings and sales estimates in the fourth quarter of 2020.

Myriad Genetics' (MYGN) Prolaris Test Study Outcome Favorable

by Zacks Equity Research

Myriad Genetics' (MYGN) new study combines a Prolaris molecular risk score approach with a clinical model for predicting a patient's benefit from androgen deprivation therapy.

Seagen (SGEN) Gets European Commission Nod for Breast Cancer Drug

by Zacks Equity Research

The European Commission approves Seagen's (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with HER2-positive locally advanced or metastatic breast cancer.

Pfizer (PFE) Gets FDA Nod for New Indication of Immunoglobulin

by Zacks Equity Research

Pfizer's (PFE) Panzyga gets FDA approval to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disease.

Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Alkermes (ALKS) beats both earnings and sales estimates in the fourth quarter of 2020.

Ultragenyx (RARE) Q4 Loss Narrows Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports a narrower year-over-year loss and sales beat estimates in the fourth quarter of 2020.

Seagen (SGEN) Submits BLA to FDA for Cervical Cancer Drug

by Zacks Equity Research

Seagen (SGEN) submits a BLA to the FDA for accelerated approval of tisotumab vedotin in patients with recurrent/metastatic cervical cancer, whose disease has progressed on or after chemotherapy.

Sesen Bio (SESN) Surges: Stock Moves 6.4% Higher

by Zacks Equity Research

Sesen Bio (SESN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Deciphera (DCPH) Reports Narrower-Than-Expected Q4 Loss

by Zacks Equity Research

Deciphera Pharmaceuticals (DCPH) reports narrower-than-expected loss. Nonetheless, sales marginally surpass estimates for the fourth quarter of 2020.

Alexion (ALXN) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Alexion Pharmaceuticals (ALXN) beats earnings and sales estimates for the fourth quarter of 2020.

Horizon Therapeutics (HZNP) to Acquire Viela Bio for $3.05B

by Zacks Equity Research

Horizon Therapeutics (HZNP) is set to buy Viela Bio for $3.05 billion to expand its pipeline and accelerate growth.

Abbott's (ABT) Nutrition & Diabetes Care Beat COVID-19 Woes

by Zacks Equity Research

Within pediatric nutrition, Abbott (ABT) registers U.S. sales growth led by increased market share of Similac infant formula brand.

Incyte (INCY) Gets Positive CHMP Opinion for Pemigatinib

by Zacks Equity Research

Incyte's (INCY) pemigatinib gets positive CHMP opinion by the EMA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.

Dr. Reddy's (RDY) Q3 Earnings Decline Y/Y, Sales Increase

by Zacks Equity Research

Dr. Reddy's (RDY) earnings decline while sales grow year over year in third-quarter fiscal 2021.

Illumina (ILMN) New Collaboration to Aid Genomics Startups

by Zacks Equity Research

Illumina (ILMN) partners with Sequoia Capital China to set up a genomics-focused startup incubator in China.

Global Blood's (GBT) MAA for Oxbryta Accepted in Europe

by Zacks Equity Research

Global Blood's (GBT) Marketing Authorization Application for the label expansion of Oxbryta tablets has been accepted by the European Medicines Agency.

Vertex's (VRTX) Trikafta NDA Gets Priority Review by FDA

by Zacks Equity Research

Vertex's (VRTX) sNDA seeking approval for Trikafta to treat cystic fibrosis in children has been accepted by the FDA.

BioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo

by Zacks Equity Research

BioCryst (BCRX) gets approval in Japan for oral, once-daily Orladeyo 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years or older.

Ultragenyx's (RARE) IND for Wilson Disease Cleared by FDA

by Zacks Equity Research

Ultragenyx's (RARE) IND application for UX701 for the treatment of Wilson Disease gets FDA clearance.

Cocrystal Pharma (COCP) Completes Research Obligations With Merck

by Zacks Equity Research

Cocrystal (COCP) completes all research obligations under the Merck exclusive worldwide license and collaboration agreement.

Bausch Health (BHC) Dry Eye Treatment Study Enrollment Complete

by Zacks Equity Research

Bausch Health (BHC) and Novaliq GmbH complete enrollment in first of the two phase III studies evaluating NOV03 to treat the signs and symptoms of Dry eye disease associated with MGD.

Acorda (ACOR) Soars on Sale of Manufacturing Unit for Inbrija

by Zacks Equity Research

Acorda (ACOR) inks an agreement to sell its Inbrija manufacturing operations in Chelsea for $80 million to Catalent. The company also announces a corporate restructuring plan to save costs. Shares up.

What Makes Acorda (ACOR) a New Buy Stock

by Zacks Equity Research

Acorda (ACOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Implied Volatility Surging for Acorda (ACOR) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Acorda (ACOR) stock based on the movements in the options market lately.